Boston Scientific completes CryoCor buyout for expanded heart therapy technology
Boston Scientific has completed its previously announced acquisition of CryoCor, a medical device company focused on cardiac arrhythmia treatments.
Under the terms of the transaction, all remaining outstanding CryoCor shares are entitled to receive a total of approximately $17.6 million, according to the Natick, Mass.-based Boston Scientific. The transaction follows the definitive agreement announced April 16.
CryoCor is now an indirect, wholly owned subsidiary of Boston Scientific.
As a result, Boston Scientific will have to combat the lawsuit filed in May against CryoCor, its board of directors and Boston Scientific by two alleged holders of CryCor’s common stock in the Superior Court of the State of California, County of San Diego.
Under the terms of the transaction, all remaining outstanding CryoCor shares are entitled to receive a total of approximately $17.6 million, according to the Natick, Mass.-based Boston Scientific. The transaction follows the definitive agreement announced April 16.
CryoCor is now an indirect, wholly owned subsidiary of Boston Scientific.
As a result, Boston Scientific will have to combat the lawsuit filed in May against CryoCor, its board of directors and Boston Scientific by two alleged holders of CryCor’s common stock in the Superior Court of the State of California, County of San Diego.